Regenerative Strategies for Hair Loss: What Can Restore a Follicle—and What Is Still Experimental

Edited and Approved by Stephen C. Rose, PhD, MS

Hair loss treatments are often described as if they all do the same job. They do not. Some slow the signals that shrink vulnerable follicles. Some push resting follicles back into growth. Transplantation relocates follicles from one part of the scalp to another. Regenerative medicine aims at something more ambitious: repairing a damaged follicular environment, restoring the function of miniaturized follicles, or eventually creating new follicles when too few remain.

That ambition is scientifically reasonable because a hair follicle is not a passive tube. It is a small, cycling organ containing epithelial stem cells, pigment-producing cells, blood vessels, immune cells, and a signaling center called the dermal papilla. These parts coordinate three repeating phases: anagen, when hair grows; catagen, when the follicle regresses; and telogen, when it rests. Reviews of regenerative hair research now group the leading strategies into platelet products, controlled micro-injury, cell therapy, cell-derived secretions and vesicles, and tissue-engineered follicles [1]. Their evidence, however, ranges from moderate human trial data to promising experiments in dishes and animals.

First identify what is being regenerated

The main target in this research is androgenetic alopecia, commonly called male or female pattern hair loss. In genetically susceptible follicles, androgen signaling—especially through dihydrotestosterone—gradually shortens the growth phase and miniaturizes thick terminal hairs into finer, shorter hairs. Topical minoxidil and oral finasteride remain widely used treatments, but they require continued use and do not reliably rebuild follicles that have disappeared. Other causes of hair loss, including autoimmune alopecia areata, scarring alopecia, thyroid disease, iron deficiency, medication effects, and acute shedding after illness, have different biology and may require entirely different treatment [2]. A regenerative procedure cannot compensate for the wrong diagnosis.

The word regeneration also needs discipline. Increasing the number of visible hairs by awakening miniaturized follicles is meaningful, but it is not the same as creating brand-new follicles. Most clinical approaches available today are better described as follicle revitalization. True follicle neogenesis—the construction of a new, correctly oriented mini-organ that repeatedly cycles and produces a cosmetically useful hair—remains largely a laboratory goal.

Platelet-rich plasma has the strongest clinical foothold

Platelet-rich plasma, or PRP, is prepared from a patient's own blood and injected into the scalp. Concentrated platelets release signaling proteins involved in wound repair, blood-vessel growth, inflammation, and cell survival. The aim is not to transplant stem cells but to improve the local signaling environment around existing follicles.

Among regenerative approaches, PRP has the broadest human evidence. A 2025 systematic review and meta-analysis evaluated 43 randomized trials with 1,877 participants. Activated PRP improved hair density and reduced hair loss compared with controls, but it did not produce a significant overall improvement in hair thickness. The authors rated the evidence as moderate and emphasized substantial variation in preparation, activation, injection schedules, control treatments, and reporting [3]. That variability matters: PRP is not one standardized drug. Two clinics can use the same label while delivering biologically different products. Results may also fade, making maintenance treatments necessary.

Microneedling uses injury as a signal

Microneedling creates controlled, shallow punctures in the scalp. The resulting wound response can release growth factors, alter inflammatory signaling, and activate pathways associated with follicle cycling. It may also improve the penetration of topical medication. A 2025 meta-analysis of 12 randomized trials involving 631 people found that microneedling combined with minoxidil improved hair counts more than minoxidil alone. Yet results varied greatly across studies, and the analysis could not identify a clearly superior needle depth, device, or treatment duration [4]. The evidence supports microneedling mainly as an adjunct, not as proof that controlled injury creates new human follicles. It should be performed with appropriate infection control and attention to scarring risk.

Cells and secretomes try to repair the follicular neighborhood

Mesenchymal stromal cells, often obtained from fat, secrete mixtures of growth factors, cytokines, lipids, and other signals. Researchers can administer cells, conditioned culture fluid, or the cell-free collection of secreted molecules known as the secretome. The appeal is that these signals might support dermal papilla cells, calm harmful inflammation, promote blood-vessel growth, and encourage resting follicles to re-enter anagen.

Human evidence is early. In one 2025 comparative study, 60 participants received minoxidil, an adipose-derived stem-cell secretome, or both for 12 weeks. All three groups improved, with the combination group reporting the strongest hair-growth measurements [5]. The study is encouraging but small, short, and not sufficient to establish durability, an optimal formulation, or superiority over well-tested care. A secretome is also a complex manufactured mixture; its activity depends on the cell source, culture conditions, purification, storage, and dose.

A more direct approach uses dermal sheath cup cells taken from healthy follicles at the back of the scalp. These cells help maintain the follicle's inductive signaling environment. In a randomized, placebo-controlled dose-finding study of 65 adults, a single injection of autologous cultured cells increased total hair density and cumulative hair diameter at one dose after six and nine months, without serious adverse events; the benefit was temporary and was no longer significant at 12 months [6]. A later single-arm multicenter study treated 36 participants twice. Thirty percent improved on blinded global photographs, while 62.9% reported some improvement; measured changes were modest and there was no placebo group [7]. These studies show biological activity, not a finished cure.

Exosomes carry messages, but the products are not interchangeable

Extracellular vesicles are nanoscale membrane packages released by cells. Exosomes are one vesicle category. They can carry proteins, lipids, messenger RNA, and microRNA to other cells, making them attractive as cell-free delivery systems. Laboratory studies suggest that vesicles from dermal papilla or mesenchymal cells can stimulate follicular cells, influence Wnt/β-catenin and other growth pathways, and promote hair growth in animal or ex vivo models [8].

The clinical evidence is much thinner than the marketing. Products called exosomes may differ in cell source, purification, cargo, sterility, potency, and even whether they contain the vesicles claimed on the label. The U.S. Food and Drug Administration states that there are currently no FDA-approved exosome products and has warned about serious adverse events involving unapproved products [9]. For hair loss, commercial availability should not be confused with regulatory approval or evidence of long-term safety.

Hair cloning and organoids remain the long game

The ultimate regenerative goal is an unlimited supply of new follicles. In this context, hair cloning usually means expanding hair-inductive cells outside the body and combining them with the epithelial cells needed to assemble follicles; it does not mean cloning a person. Scientists have learned that dermal papilla cells rapidly lose their hair-forming identity when expanded on flat culture dishes. Three-dimensional spheroids, biomaterial scaffolds, skin organoids, and carefully timed developmental signals can preserve or restore some of that identity. Researchers have produced follicle-containing skin structures in laboratory systems, but creating thousands of consistently oriented, pigmented, cycling human follicles that safely integrate into an adult scalp is a much harder manufacturing problem [10].

How to judge a regenerative hair-loss claim

The field is moving, but at several different speeds. PRP has moderate evidence for improving density in some people with pattern hair loss, though protocols remain inconsistent. Microneedling has supportive evidence as an adjunct to minoxidil. Secretome and dermal sheath cell treatments have preliminary human signals but need larger controlled trials, standardized manufacturing, and longer follow-up. Exosome therapies remain experimental, and engineered follicles or hair cloning are not routine clinical treatments.

Before paying for a procedure, patients should ask what diagnosis is being treated, whether the product is autologous or donor-derived, how it is processed, what controlled human trial supports the exact formulation, what outcome was measured, how long benefits lasted, and what regulatory authorization applies. A photograph, testimonial, or laboratory pathway is not equivalent to a randomized clinical result. The most realistic near-term future is probably combination care: established treatments preserving vulnerable follicles while carefully standardized regenerative tools improve the local environment. True replacement of lost follicles remains a compelling scientific destination—but it has not yet become an off-the-shelf medical reality.

References

[1] Shimizu Y, Ntege EH, Sunami H, Inoue Y. Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature. Regen Ther. 2022;21:527-539. doi:10.1016/j.reth.2022.10.005.

[2] Shin JW, Huh CH. Updates in Treatment for Androgenetic Alopecia. Ann Dermatol. 2025;37(6):327-335. doi:10.5021/ad.25.042.

[3] Anitua E, Tierno R, Alkhraisat MH. Platelet-Rich Plasma in the Management of Alopecia: A Systematic Review and Meta-Analysis of Clinical Evidence. Dermatol Ther (Heidelb). 2025;15(11):3213-3252. doi:10.1007/s13555-025-01542-8.

[4] Ahmed KMA, Kozaa YA, Abuawwad MT, et al. Evaluating the efficacy and safety of combined microneedling therapy versus topical Minoxidil in androgenetic alopecia: a systematic review and meta-analysis. Arch Dermatol Res. 2025;317(1):528. doi:10.1007/s00403-025-04032-1.

[5] Legiawati L, Sitohang IBS, Yusharyahya SN, et al. Hair regeneration in androgenetic alopecia using secretome of adipose-derived stem cells (ADSC) and minoxidil: a comparative study of three groups. Arch Dermatol Res. 2025;317(1). doi:10.1007/s00403-025-04006-3.

[6] Tsuboi R, Niiyama S, Irisawa R, et al. Autologous cell-based therapy for male and female pattern hair loss using dermal sheath cup cells: A randomized placebo-controlled double-blinded dose-finding clinical study. J Am Acad Dermatol. 2020;83(1):109-116. doi:10.1016/j.jaad.2020.02.033.

[7] Harada K, Ohyama M, Niiyama S, et al. Efficacy of autologous dermal sheath cup cell transplantation in male and female pattern hair loss: A single-arm, multi-center, phase III equivalent clinical study. J Dermatol. 2023;50(12):1539-1549. doi:10.1111/1346-8138.16957.

[8] Gangadaran P, Rajendran RL, Kwack MH, et al. Application of Cell-Derived Extracellular Vesicles and Engineered Nanovesicles for Hair Growth: From Mechanisms to Therapeutics. Front Cell Dev Biol. 2022;10:963278. doi:10.3389/fcell.2022.963278.

[9] U.S. Food and Drug Administration. Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products. Posted December 9, 2019. Accessed September 7, 2026.

[10] Castro AR, Logarinho E. Tissue engineering strategies for human hair follicle regeneration: How far from a hairy goal? Stem Cells Transl Med. 2020;9(3):342-350. doi:10.1002/sctm.19-0301.